Paternal mononuclear cell immunization therapy for repeated miscarriage: predictive variables for pregnancy success.
Pregnancy outcomes for 125 women with unexplained recurrent abortion conceiving after immunologic testing for possible paternal leukocyte immunization were analyzed. Pregnancy success was related to the number of previous miscarriages (relative risk 0.36 for each additional miscarriage after 3), a history of a late pregnancy loss (relative risk 0.18), any other relevant treated or untreatable diagnosis (relative risk 0.27), immunization with paternal mononuclear cells (relative risk 5.6), and time in weeks from test date to LMP of the next pregnancy (relative risk 0.93 for each additional week). The significant difference in pregnancy outcomes between women given a single immunization and nonimmunized women reflected a larger difference between those in each group conceiving within 12 weeks of initiating tests for inclusion in the treatment program. The latter observation suggests that any effect from a single immunization in prevention of recurrent miscarriage is of relatively short duration.
Cowchock
F S
FS
Department of Internal Medicine, Jefferson Medical College, Philadelphia, PA 19107.
Smith
J B
JB
David
S
S
Scher
J
J
Batzer
F
F
Corson
S
S
D000026:Abortion, Habitual / Q000276:immunology / Q000517:prevention & control*; D000328:Adult; D005220:Fathers; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D007114:Immunization; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D007959:Lymphocyte Culture Test, Mixed; D008297:Male; D011247:Pregnancy; D011256:Pregnancy Outcome; D013997:Time Factors